CONMED (NYSE:CNMD) Releases FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.250-4.400 for the period, compared to the consensus estimate of 4.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Stock Performance

NYSE CNMD traded down $5.74 during trading hours on Thursday, hitting $68.26. 438,605 shares of the stock were exchanged, compared to its average volume of 415,689. The company has a market cap of $2.11 billion, a price-to-earnings ratio of 16.30, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46. CONMED has a 12-month low of $61.05 and a 12-month high of $88.60. The stock has a 50-day moving average of $70.64 and a 200 day moving average of $70.22. The company has a quick ratio of 1.06, a current ratio of 2.27 and a debt-to-equity ratio of 1.01.

CONMED (NYSE:CNMD) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.23% and a return on equity of 13.84%. As a group, equities research analysts forecast that CONMED will post 4.03 earnings per share for the current year.

CONMED Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 annualized dividend and a yield of 1.17%. CONMED’s dividend payout ratio is presently 19.00%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CNMD. StockNews.com cut CONMED from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reduced their price objective on CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a report on Thursday. JPMorgan Chase & Co. cut CONMED from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $85.00 to $70.00 in a report on Thursday. Finally, Wells Fargo & Company reduced their price objective on CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, CONMED currently has an average rating of “Moderate Buy” and an average price target of $77.40.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.